These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12527997)

  • 1. Periodic leg movements in patients with Parkinson's disease are associated with reduced striatal dopamine transporter binding.
    Happe S; Pirker W; Klösch G; Sauter C; Zeitlhofer J
    J Neurol; 2003 Jan; 250(1):83-6. PubMed ID: 12527997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.
    Scherfler C; Seppi K; Donnemiller E; Goebel G; Brenneis C; Virgolini I; Wenning GK; Poewe W
    Brain; 2005 Jul; 128(Pt 7):1605-12. PubMed ID: 15817519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sleep microstructure and neurodegeneration as measured by [123I]beta-CIT SPECT in treated patients with Parkinson's disease.
    Happe S; Anderer P; Pirker W; Klösch G; Gruber G; Saletu B; Zeitlhofer J
    J Neurol; 2004 Dec; 251(12):1465-71. PubMed ID: 15645345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease.
    Stoffers D; Booij J; Bosscher L; Winogrodzka A; Wolters EC; Berendse HW
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):689-95. PubMed ID: 15682332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.
    Ichise M; Kim YJ; Erami SS; Ballinger JR; Vines D; Tanaka F; Lang AE
    J Nucl Med; 1999 Apr; 40(4):530-8. PubMed ID: 10210210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective measures for the progression of Parkinson's disease.
    Snow B
    J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):287. PubMed ID: 12588908
    [No Abstract]   [Full Text] [Related]  

  • 9. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT.
    Pirker W; Holler I; Gerschlager W; Asenbaum S; Zettinig G; Brücke T
    Mov Disord; 2003 Nov; 18(11):1266-72. PubMed ID: 14639666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.
    Berding G; Brücke T; Odin P; Brooks DJ; Kolbe H; Gielow P; Harke H; Knoop BO; Dengler R; Knapp WH
    Nuklearmedizin; 2003 Feb; 42(1):31-8. PubMed ID: 12601452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
    Marek K; Innis R; van Dyck C; Fussell B; Early M; Eberly S; Oakes D; Seibyl J
    Neurology; 2001 Dec; 57(11):2089-94. PubMed ID: 11739831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.
    Tissingh G; Bergmans P; Booij J; Winogrodzka A; van Royen EA; Stoof JC; Wolters EC
    J Neurol; 1998 Jan; 245(1):14-20. PubMed ID: 9457623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Tissingh G; Bergmans P; Winogrodzka A; Stoof JC; Wolters EC; Booij J; Van Royen EA
    J Nucl Med; 1997 Aug; 38(8):1271-2. PubMed ID: 9255164
    [No Abstract]   [Full Text] [Related]  

  • 17. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
    Gerschlager W; Bencsits G; Pirker W; Bloem BR; Asenbaum S; Prayer D; Zijlmans JC; Hoffmann M; Brücke T
    Mov Disord; 2002 May; 17(3):518-23. PubMed ID: 12112200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease.
    Hwang WJ; Yao WJ; Wey SP; Ting G
    J Nucl Med; 2004 Feb; 45(2):207-13. PubMed ID: 14960637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.